OncoMatch

OncoMatch/Clinical Trials/NCT05647122

First in Human Study of AZD9592 in Solid Tumors

Is NCT05647122 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for advanced solid tumours.

Phase 1RecruitingAstraZenecaNCT05647122Data as of May 2026

Treatment: AZD9592 · Osimertinib · 5-Fluorouracil (5-FU) · Leucovorin · Bevacizumab — This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Head and Neck Squamous Cell Carcinoma

Colorectal Cancer

Biomarker criteria

Required: EGFR mutation

Required: EGFR wild-type

Disease stage

Metastatic disease required

measurable disease per RECIST v1.1; metastatic or locally advanced

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

adequate organ and marrow function as defined in the protocol

Kidney function

adequate organ and marrow function as defined in the protocol

Liver function

adequate organ and marrow function as defined in the protocol

Cardiac function

participants with cardiac comorbidities as defined in the study protocol [excluded]

Adequate organ and marrow function as defined in the protocol; participants with cardiac comorbidities as defined in the study protocol [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Milford, Massachusetts
  • Research Site · Mineola, New York
  • Research Site · New York, New York
  • Research Site · New York, New York
  • Research Site · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify